Presentation Details<\/h2>\n\n- Title<\/b>: The Discovery and Development of a CD3 Agonistic Single Domain Antibody to Accelerate the Development of CD3 T Cell Engager Multi-Specific Antibodies<\/li>\n
- Session Title<\/b>: Therapeutic Antibodies, Including Engineered Antibodies 2<\/li>\n
- Session Date and Time<\/b>: April 29, 2025 at 2-5 PM<\/li>\n
- Location<\/b>: Poster Section 35<\/li>\n
- Poster Board Number<\/b>: 1<\/li>\n
- Published Abstract Number<\/b>: 6006<\/li>\n
- View Abstract<\/b>: https:\/\/www.abstractsonline.com\/pp8\/#!\/20273\/presentation\/1890<\/a><\/li>\n<\/ul>\n\n<\/div>\n
About ProBio\u2019s T-Cell Engager and Antibody Discovery Platform<\/h2>\n\n
CD3 T-cell engagers (TCEs) are a promising strategy in cancer immunotherapy, that are often constrained by safety concerns, potency limitations, and design challenges. ProBio\u2019s proprietary platform utilizes an optimized single-domain antibody (sdAb) targeting CD3, overcoming these challenges by enablingthe development of highly adaptable bispecific and multi-specific antibodies. These antibodies show enhanced tumor-killing activity and improved safety profiles. Preclinical studies have demonstrated robust T-cell activation, tumor growth inhibition, and overall therapeutic potential.<\/p>\n
ProBio\u2019s approach is supported by a fully integrated Contract Development and Manufacturing Organization (CDMO) model that spans discovery through IND-enabling studies with scalable Chemistry, Manufacturing, and Controls (CMC) development and GMP drug product manufacturing. This seamless approach allows biotech and pharmaceutical partners to transition efficiently from early-stage concepts to clinical and commercial production, reducing development risks and accelerating timelines.<\/p>\n
\u201cOur CD3 single-domain antibody platform represents the innovation needed to address some of most pressing challenges in immune-oncology \u2013 delivering potent, modular, and clinically translatable solutions,\u201d said Dr. Yu Liang, Head of Discovery at ProBio<\/b>. \u201cBy combining deep scientific expertise with end-to-end development capabilities, we\u2019re accelerating the pace at which our partners can bring transformative immunotherapies to the clinic.\u201d<\/p>\n
ProBio remains committed to partnering with global innovators to accelerate the development of novel immunotherapies, advancing the standard of care for both solid and liquid tumors.<\/p>\n\n\n\n
<\/div>\nABOUT PROBIO<\/h2>\n\n\n
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.<\/p>\n
Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new molecules. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches.<\/p>\n\n"}],"cooperationDataEN":[{"id":"20717","loc_code":"US","name":"cooperation","alias":"cooperation","active":"1","create_date":"2024-11-15 04:27:02","modified_date":"2024-11-15 19:42:42","special_id":"6","content_id":"20685","show_time":"2024-11-15 00:00:00","content_name":"GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer - ProBio","type":"string","owner_id":"84","parent_id":"20384","template_id":"2244","item_order":"69","hierarchy":"00002.00069","default_content":"0","menu_text":"GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer","content_alias":"genscript-subsidiary-probio-instrumental-in-latest-fight-against-cancer","show_in_menu":"0","show_link_in_menu":"0","collapsed":null,"markup":"html","cachable":"1","id_hierarchy":"20384.20685","hierarchy_path":null,"prop_names":"content_en","metadata":"\n\n\n","titleattribute":null,"tabindex":null,"accesskey":null,"last_modified_by":"84","gs_hierarchy":null,"searchable":"1","prop_name":"content_en","param1":null,"param2":null,"param3":null,"content":"
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer<\/h1>\n\n<\/div>\nPISCATAWAY, NJ \u2014 November 15, 2024: GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.<\/p>\n
<\/div>\n\n ![](\"\/img\/news\/genscript-probio-inc-enters-into-exclusive-licensing-agreement-with-laNova-medicines-for-anti-pd-1-cancer-therapy-img.png\")
\n<\/div>\n<\/div>\nLaNova Medicines leveraged ProBio\u2019s PD-1 molecule to develop its PD-1\/VEGF bispecific antibody, a key component of the LM-299 program. Following LaNova\u2019s recent agreement with Merck, GenScript projects that ProBio\u2019s partnership with LaNova could generate significant revenue for ProBio, as LaNova Medicines has entered into an exclusive agreement with Merck & Co., Inc for LM-299 for a reported $3.3B.<\/p>\n\n
\"We congratulate LaNova Medicines for unlocking the therapeutic potential of our anti-PD-1 NME to treat patients in need,\" said Patrick Liu, Chair of ProBio's Board of Directors. \"This agreement demonstrates ProBio's robust business model, which combines innovative NME development with collaborative process development and manufacturing capabilities.\"<\/p>\n\n
The agreement underscores ProBio's commitment to delivering cutting-edge therapies, reinforces its position as a leader in immuno-oncology, and differentiates it from other CDMOs.<\/p>\n
ProBio\u2019s PD-1 is a key component of anti-cancer treatments, and represents the next generation in the fight against cancer.<\/p>\n
GenScript has strategic plans underway to expand its global manufacturing capacity, including at ProBio\u2019s site in Hopewell, NJ and this financial boost will further support those initiatives.<\/p>\n\n
<\/div>\nAbout GenScript<\/h2>\n
GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacturing. Built upon its solid DNA synthesis technology, the corporation comprises three business units: life-science services and products, a biologics contract development and manufacturing organization (CDMO), and industrial synthetic enzymes business unit. GenScript accelerates scientific discovery and therapeutic breakthroughs with its customers. Since its founding in Piscataway, New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of over 5400 employees. More than 100,000 peer-reviewed journal articles worldwide have cited GenScript \u2019s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.<\/p>\n
For more information, please visit GenScript\u2019s official websit https:\/\/www.genscript.com<\/a>.<\/p>\n\n<\/div>\nAbout ProBio Inc<\/h2>\n
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.<\/p>\n\n
Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new molecular entities. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches. For more information on our New Molecular Entities program and existing assets, please visit https:\/\/hubs.ly\/Q02Yj0CZ0<\/a>.<\/p>\n\nTo learn more about ProBio services, please visit www.probiocdmo.com<\/a><\/p>\n\n\n<\/div>"}],"awardDataEN":[{"id":"20523","loc_code":"US","name":"awards","alias":"awards","active":"1","create_date":"2021-11-09 01:53:31","modified_date":"2024-11-04 01:42:40","special_id":"7","content_id":"20488","show_time":"2021-11-09 00:00:00","content_name":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific - ProBio","type":"string","owner_id":"84","parent_id":"20384","template_id":"2244","item_order":"32","hierarchy":"00002.00032","default_content":"0","menu_text":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific","content_alias":"genscript-probio-named-a-top-10-drug-discovery-solution-provider-in-asia-pacific","show_in_menu":"0","show_link_in_menu":"0","collapsed":null,"markup":"html","cachable":"1","id_hierarchy":"20384.20488","hierarchy_path":null,"prop_names":"content_en","metadata":"\n\n\n","titleattribute":null,"tabindex":null,"accesskey":null,"last_modified_by":"84","gs_hierarchy":null,"searchable":"1","prop_name":"content_en","param1":null,"param2":null,"param3":null,"content":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific<\/h1>\n
Recently, ProBio is selected as one of the \u201cTop 10 Drug Discovery Solution Providers in Asia-Pacific 2021\u201d by Pharma Tech Outlook magazine. The purpose of this award is to discover new forces that are rapidly developing in the Asia-Pacific region, so that more industry players can see some fast-growing companies with a sense of industry responsibility. Based on data analysis of industry and evaluation by experts from the editorial board, ProBio was named \"Top 10 Drug Discovery Solution Providers in Asia-Pacific 2021\" for its outstanding performance.<\/p>\n
\n ![](\"\/img\/news\/genscript-probio-named-a-top-10-drug-discovery-solution-provider-in-asia-pacific-image1.jpg\")
\n<\/div>\n<\/div>\nDr. Brian Min, CEO of ProBio, accepted an interview with the magazine. The editorial board of Pharma Tech Outlook was deeply impressed by ProBio\u2019s outstanding performance in the field of antibody drug discovery, and selected ProBio\u2019s CEO Dr. Brian Min as the cover character of the issue of \"Drug Discovery APAC 2021 edition\". The following is a summary of the interview.<\/p>\n
\n ![](\"\/img\/news\/genscript-probio-named-a-top-10-drug-discovery-solution-provider-in-asia-pacific-image2.jpg\")
\n<\/div>\n<\/div>\n\n ![](\"\/img\/news\/genscript-probio-named-a-top-10-drug-discovery-solution-provider-in-asia-pacific-image3.jpg\")
\n<\/div>\n<\/div>\nThe efficacy of clinical trials for drug discovery and development hinges on identifying a suitable compound that could eventually lead to the development of a credible pharmaceutical product. That said, pharmaceutical manufacturers have failed to capitalize on the market potential, often developing defective products that barely pass the clinical trial, let alone succeed in the marketplace. A primary factor attributed to such unnecessary expenditure is the lack of comprehensive knowledge on molecules, alongside improper clinical trial management or inadequate quality management. Safe to say, these inadequacies have weighed down on drug developers and manufacturers.<\/p>\n
ProBio empowers pharmaceutical organizations and its valued stakeholders to fuel the development of relevant molecules and produce therapeutic antibody candidates for disease causing multi-membrane proteins. As pharmaceutical companies enter new avenues to study sophisticated molecule structures for more complex targets\/illnesses, ProBio\u2019s extensive scientific know-how and subject matter expertise allows them to offer services, covering research and manufacturing workflow with uncompromised quality. \u201cAs of October 2021, we have completed over 950 projects, including nearly 200 projects for antibody discovery of multi transmembrane targets,\u201d says Dr. Brian Min, CEO of ProBio.<\/p>\n
In addition to its extensive experience, ProBio is committed to building an industry-leading platform for antibody drug technology. ProBio\u2019s Single B Cell Antibody Discovery<\/a> system allows pharmaceuticals to speed up the process and complete the process in quick succession of time. Another trend that ProBio addresses is Bispecific Antibody<\/a> Discovery. The Drug Discovery solution provider offers its clients a SMABody platform that enables them to have access to various options to develop Bispecific antibodies without any license fee. Its excellent track records in working with multi transmembrane molecule targets provides unparalleled leadership in the drug discovery field. Up to now, ProBio has helped global customers obtain 9 IND approvals.<\/p>\nMoreover, \u201cWe can help our clients through the tough regulatory landscape and assist them in obtaining approval for their projects,\u201d says Dr. Min. ProBio follows the international leading design concept and is a true \"zero-crossover, unidirectional flow\" plant, which meets FDA, EMA and NMPA regulatory requirements.<\/p>\n
Offering pharma companies, a wholesome experience in outsourcing services and solutions, ProBio also shares its advice and makes suggestions for new players in the drug discovery space. \u201cUltimately, our clients are the decision-makers, but based on our experience and scientific knowledge in drug discovery CRO and Biologics CDMO services<\/a>, we can suggest the best approach to produce a therapeutic antibody,\u201d says Dr. Min. In setting the standard for drug\ndiscovery service delivery, ProBio has worked alongside many pharmaceuticals to provide an end-to-end approach with zero hindrance in drug discovery and production. \u201cOur\ncapability to rapidly develop multi transmembrane targets that are complex and sophisticated for biologics product development with a success rate of above eighty-five percent allows us to continue innovating to serve our clients with even more efficiency,\u201d concludes Dr. Min.<\/p>\nFor detailed interview content, please click the link <\/a><\/p>\nAbout Pharma Tech Outlook<\/h2>\n
Pharma Tech Outlook is a print and digital magazine with over 130,000 qualified subscribers across the APAC, providing a curated platform for technologists and business insiders from the pharmaceutical industry to explore the latest technology trends and understand how their peers leverage new technology.<\/p>"}]}
About ProBio\u2019s T-Cell Engager and Antibody Discovery Platform<\/h2>\n\n
CD3 T-cell engagers (TCEs) are a promising strategy in cancer immunotherapy, that are often constrained by safety concerns, potency limitations, and design challenges. ProBio\u2019s proprietary platform utilizes an optimized single-domain antibody (sdAb) targeting CD3, overcoming these challenges by enablingthe development of highly adaptable bispecific and multi-specific antibodies. These antibodies show enhanced tumor-killing activity and improved safety profiles. Preclinical studies have demonstrated robust T-cell activation, tumor growth inhibition, and overall therapeutic potential.<\/p>\n
ProBio\u2019s approach is supported by a fully integrated Contract Development and Manufacturing Organization (CDMO) model that spans discovery through IND-enabling studies with scalable Chemistry, Manufacturing, and Controls (CMC) development and GMP drug product manufacturing. This seamless approach allows biotech and pharmaceutical partners to transition efficiently from early-stage concepts to clinical and commercial production, reducing development risks and accelerating timelines.<\/p>\n
\u201cOur CD3 single-domain antibody platform represents the innovation needed to address some of most pressing challenges in immune-oncology \u2013 delivering potent, modular, and clinically translatable solutions,\u201d said Dr. Yu Liang, Head of Discovery at ProBio<\/b>. \u201cBy combining deep scientific expertise with end-to-end development capabilities, we\u2019re accelerating the pace at which our partners can bring transformative immunotherapies to the clinic.\u201d<\/p>\n
ProBio remains committed to partnering with global innovators to accelerate the development of novel immunotherapies, advancing the standard of care for both solid and liquid tumors.<\/p>\n\n\n\n
ABOUT PROBIO<\/h2>\n\n\n
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.<\/p>\n
Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new molecules. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches.<\/p>\n\n"}],"cooperationDataEN":[{"id":"20717","loc_code":"US","name":"cooperation","alias":"cooperation","active":"1","create_date":"2024-11-15 04:27:02","modified_date":"2024-11-15 19:42:42","special_id":"6","content_id":"20685","show_time":"2024-11-15 00:00:00","content_name":"GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer - ProBio","type":"string","owner_id":"84","parent_id":"20384","template_id":"2244","item_order":"69","hierarchy":"00002.00069","default_content":"0","menu_text":"GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer","content_alias":"genscript-subsidiary-probio-instrumental-in-latest-fight-against-cancer","show_in_menu":"0","show_link_in_menu":"0","collapsed":null,"markup":"html","cachable":"1","id_hierarchy":"20384.20685","hierarchy_path":null,"prop_names":"content_en","metadata":"\n\n\n","titleattribute":null,"tabindex":null,"accesskey":null,"last_modified_by":"84","gs_hierarchy":null,"searchable":"1","prop_name":"content_en","param1":null,"param2":null,"param3":null,"content":"
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer<\/h1>\n\n<\/div>\nPISCATAWAY, NJ \u2014 November 15, 2024: GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.<\/p>\n
<\/div>\n\n \n<\/div>\n<\/div>\nLaNova Medicines leveraged ProBio\u2019s PD-1 molecule to develop its PD-1\/VEGF bispecific antibody, a key component of the LM-299 program. Following LaNova\u2019s recent agreement with Merck, GenScript projects that ProBio\u2019s partnership with LaNova could generate significant revenue for ProBio, as LaNova Medicines has entered into an exclusive agreement with Merck & Co., Inc for LM-299 for a reported $3.3B.<\/p>\n\n
\"We congratulate LaNova Medicines for unlocking the therapeutic potential of our anti-PD-1 NME to treat patients in need,\" said Patrick Liu, Chair of ProBio's Board of Directors. \"This agreement demonstrates ProBio's robust business model, which combines innovative NME development with collaborative process development and manufacturing capabilities.\"<\/p>\n\n
The agreement underscores ProBio's commitment to delivering cutting-edge therapies, reinforces its position as a leader in immuno-oncology, and differentiates it from other CDMOs.<\/p>\n
ProBio\u2019s PD-1 is a key component of anti-cancer treatments, and represents the next generation in the fight against cancer.<\/p>\n
GenScript has strategic plans underway to expand its global manufacturing capacity, including at ProBio\u2019s site in Hopewell, NJ and this financial boost will further support those initiatives.<\/p>\n\n
<\/div>\nAbout GenScript<\/h2>\n
GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacturing. Built upon its solid DNA synthesis technology, the corporation comprises three business units: life-science services and products, a biologics contract development and manufacturing organization (CDMO), and industrial synthetic enzymes business unit. GenScript accelerates scientific discovery and therapeutic breakthroughs with its customers. Since its founding in Piscataway, New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of over 5400 employees. More than 100,000 peer-reviewed journal articles worldwide have cited GenScript \u2019s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.<\/p>\n
For more information, please visit GenScript\u2019s official websit https:\/\/www.genscript.com<\/a>.<\/p>\n\n<\/div>\nAbout ProBio Inc<\/h2>\n
ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.<\/p>\n\n
Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new molecular entities. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches. For more information on our New Molecular Entities program and existing assets, please visit https:\/\/hubs.ly\/Q02Yj0CZ0<\/a>.<\/p>\n\nTo learn more about ProBio services, please visit www.probiocdmo.com<\/a><\/p>\n\n\n<\/div>"}],"awardDataEN":[{"id":"20523","loc_code":"US","name":"awards","alias":"awards","active":"1","create_date":"2021-11-09 01:53:31","modified_date":"2024-11-04 01:42:40","special_id":"7","content_id":"20488","show_time":"2021-11-09 00:00:00","content_name":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific - ProBio","type":"string","owner_id":"84","parent_id":"20384","template_id":"2244","item_order":"32","hierarchy":"00002.00032","default_content":"0","menu_text":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific","content_alias":"genscript-probio-named-a-top-10-drug-discovery-solution-provider-in-asia-pacific","show_in_menu":"0","show_link_in_menu":"0","collapsed":null,"markup":"html","cachable":"1","id_hierarchy":"20384.20488","hierarchy_path":null,"prop_names":"content_en","metadata":"\n\n\n","titleattribute":null,"tabindex":null,"accesskey":null,"last_modified_by":"84","gs_hierarchy":null,"searchable":"1","prop_name":"content_en","param1":null,"param2":null,"param3":null,"content":"ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific<\/h1>\n
Recently, ProBio is selected as one of the \u201cTop 10 Drug Discovery Solution Providers in Asia-Pacific 2021\u201d by Pharma Tech Outlook magazine. The purpose of this award is to discover new forces that are rapidly developing in the Asia-Pacific region, so that more industry players can see some fast-growing companies with a sense of industry responsibility. Based on data analysis of industry and evaluation by experts from the editorial board, ProBio was named \"Top 10 Drug Discovery Solution Providers in Asia-Pacific 2021\" for its outstanding performance.<\/p>\n
\n \n<\/div>\n<\/div>\nDr. Brian Min, CEO of ProBio, accepted an interview with the magazine. The editorial board of Pharma Tech Outlook was deeply impressed by ProBio\u2019s outstanding performance in the field of antibody drug discovery, and selected ProBio\u2019s CEO Dr. Brian Min as the cover character of the issue of \"Drug Discovery APAC 2021 edition\". The following is a summary of the interview.<\/p>\n
\n \n<\/div>\n<\/div>\n\n \n<\/div>\n<\/div>\nThe efficacy of clinical trials for drug discovery and development hinges on identifying a suitable compound that could eventually lead to the development of a credible pharmaceutical product. That said, pharmaceutical manufacturers have failed to capitalize on the market potential, often developing defective products that barely pass the clinical trial, let alone succeed in the marketplace. A primary factor attributed to such unnecessary expenditure is the lack of comprehensive knowledge on molecules, alongside improper clinical trial management or inadequate quality management. Safe to say, these inadequacies have weighed down on drug developers and manufacturers.<\/p>\n
ProBio empowers pharmaceutical organizations and its valued stakeholders to fuel the development of relevant molecules and produce therapeutic antibody candidates for disease causing multi-membrane proteins. As pharmaceutical companies enter new avenues to study sophisticated molecule structures for more complex targets\/illnesses, ProBio\u2019s extensive scientific know-how and subject matter expertise allows them to offer services, covering research and manufacturing workflow with uncompromised quality. \u201cAs of October 2021, we have completed over 950 projects, including nearly 200 projects for antibody discovery of multi transmembrane targets,\u201d says Dr. Brian Min, CEO of ProBio.<\/p>\n
In addition to its extensive experience, ProBio is committed to building an industry-leading platform for antibody drug technology. ProBio\u2019s Single B Cell Antibody Discovery<\/a> system allows pharmaceuticals to speed up the process and complete the process in quick succession of time. Another trend that ProBio addresses is Bispecific Antibody<\/a> Discovery. The Drug Discovery solution provider offers its clients a SMABody platform that enables them to have access to various options to develop Bispecific antibodies without any license fee. Its excellent track records in working with multi transmembrane molecule targets provides unparalleled leadership in the drug discovery field. Up to now, ProBio has helped global customers obtain 9 IND approvals.<\/p>\nMoreover, \u201cWe can help our clients through the tough regulatory landscape and assist them in obtaining approval for their projects,\u201d says Dr. Min. ProBio follows the international leading design concept and is a true \"zero-crossover, unidirectional flow\" plant, which meets FDA, EMA and NMPA regulatory requirements.<\/p>\n
Offering pharma companies, a wholesome experience in outsourcing services and solutions, ProBio also shares its advice and makes suggestions for new players in the drug discovery space. \u201cUltimately, our clients are the decision-makers, but based on our experience and scientific knowledge in drug discovery CRO and Biologics CDMO services<\/a>, we can suggest the best approach to produce a therapeutic antibody,\u201d says Dr. Min. In setting the standard for drug\ndiscovery service delivery, ProBio has worked alongside many pharmaceuticals to provide an end-to-end approach with zero hindrance in drug discovery and production. \u201cOur\ncapability to rapidly develop multi transmembrane targets that are complex and sophisticated for biologics product development with a success rate of above eighty-five percent allows us to continue innovating to serve our clients with even more efficiency,\u201d concludes Dr. Min.<\/p>\nFor detailed interview content, please click the link <\/a><\/p>\nAbout Pharma Tech Outlook<\/h2>\n
Pharma Tech Outlook is a print and digital magazine with over 130,000 qualified subscribers across the APAC, providing a curated platform for technologists and business insiders from the pharmaceutical industry to explore the latest technology trends and understand how their peers leverage new technology.<\/p>"}]}
PISCATAWAY, NJ \u2014 November 15, 2024: GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.<\/p>\n
\n<\/div>\nLaNova Medicines leveraged ProBio\u2019s PD-1 molecule to develop its PD-1\/VEGF bispecific antibody, a key component of the LM-299 program. Following LaNova\u2019s recent agreement with Merck, GenScript projects that ProBio\u2019s partnership with LaNova could generate significant revenue for ProBio, as LaNova Medicines has entered into an exclusive agreement with Merck & Co., Inc for LM-299 for a reported $3.3B.<\/p>\n\n
\"We congratulate LaNova Medicines for unlocking the therapeutic potential of our anti-PD-1 NME to treat patients in need,\" said Patrick Liu, Chair of ProBio's Board of Directors. \"This agreement demonstrates ProBio's robust business model, which combines innovative NME development with collaborative process development and manufacturing capabilities.\"<\/p>\n\n
The agreement underscores ProBio's commitment to delivering cutting-edge therapies, reinforces its position as a leader in immuno-oncology, and differentiates it from other CDMOs.<\/p>\n
ProBio\u2019s PD-1 is a key component of anti-cancer treatments, and represents the next generation in the fight against cancer.<\/p>\n
GenScript has strategic plans underway to expand its global manufacturing capacity, including at ProBio\u2019s site in Hopewell, NJ and this financial boost will further support those initiatives.<\/p>\n\n
About GenScript<\/h2>\n
GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacturing. Built upon its solid DNA synthesis technology, the corporation comprises three business units: life-science services and products, a biologics contract development and manufacturing organization (CDMO), and industrial synthetic enzymes business unit. GenScript accelerates scientific discovery and therapeutic breakthroughs with its customers. Since its founding in Piscataway, New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of over 5400 employees. More than 100,000 peer-reviewed journal articles worldwide have cited GenScript \u2019s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.<\/p>\n
For more information, please visit GenScript\u2019s official websit https:\/\/www.genscript.com<\/a>.<\/p>\n\n ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.<\/p>\n\n Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new molecular entities. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches. For more information on our New Molecular Entities program and existing assets, please visit https:\/\/hubs.ly\/Q02Yj0CZ0<\/a>.<\/p>\n\n To learn more about ProBio services, please visit www.probiocdmo.com<\/a><\/p>\n\n\n Recently, ProBio is selected as one of the \u201cTop 10 Drug Discovery Solution Providers in Asia-Pacific 2021\u201d by Pharma Tech Outlook magazine. The purpose of this award is to discover new forces that are rapidly developing in the Asia-Pacific region, so that more industry players can see some fast-growing companies with a sense of industry responsibility. Based on data analysis of industry and evaluation by experts from the editorial board, ProBio was named \"Top 10 Drug Discovery Solution Providers in Asia-Pacific 2021\" for its outstanding performance.<\/p>\n Dr. Brian Min, CEO of ProBio, accepted an interview with the magazine. The editorial board of Pharma Tech Outlook was deeply impressed by ProBio\u2019s outstanding performance in the field of antibody drug discovery, and selected ProBio\u2019s CEO Dr. Brian Min as the cover character of the issue of \"Drug Discovery APAC 2021 edition\". The following is a summary of the interview.<\/p>\n The efficacy of clinical trials for drug discovery and development hinges on identifying a suitable compound that could eventually lead to the development of a credible pharmaceutical product. That said, pharmaceutical manufacturers have failed to capitalize on the market potential, often developing defective products that barely pass the clinical trial, let alone succeed in the marketplace. A primary factor attributed to such unnecessary expenditure is the lack of comprehensive knowledge on molecules, alongside improper clinical trial management or inadequate quality management. Safe to say, these inadequacies have weighed down on drug developers and manufacturers.<\/p>\n ProBio empowers pharmaceutical organizations and its valued stakeholders to fuel the development of relevant molecules and produce therapeutic antibody candidates for disease causing multi-membrane proteins. As pharmaceutical companies enter new avenues to study sophisticated molecule structures for more complex targets\/illnesses, ProBio\u2019s extensive scientific know-how and subject matter expertise allows them to offer services, covering research and manufacturing workflow with uncompromised quality. \u201cAs of October 2021, we have completed over 950 projects, including nearly 200 projects for antibody discovery of multi transmembrane targets,\u201d says Dr. Brian Min, CEO of ProBio.<\/p>\n In addition to its extensive experience, ProBio is committed to building an industry-leading platform for antibody drug technology. ProBio\u2019s Single B Cell Antibody Discovery<\/a> system allows pharmaceuticals to speed up the process and complete the process in quick succession of time. Another trend that ProBio addresses is Bispecific Antibody<\/a> Discovery. The Drug Discovery solution provider offers its clients a SMABody platform that enables them to have access to various options to develop Bispecific antibodies without any license fee. Its excellent track records in working with multi transmembrane molecule targets provides unparalleled leadership in the drug discovery field. Up to now, ProBio has helped global customers obtain 9 IND approvals.<\/p>\n Moreover, \u201cWe can help our clients through the tough regulatory landscape and assist them in obtaining approval for their projects,\u201d says Dr. Min. ProBio follows the international leading design concept and is a true \"zero-crossover, unidirectional flow\" plant, which meets FDA, EMA and NMPA regulatory requirements.<\/p>\n Offering pharma companies, a wholesome experience in outsourcing services and solutions, ProBio also shares its advice and makes suggestions for new players in the drug discovery space. \u201cUltimately, our clients are the decision-makers, but based on our experience and scientific knowledge in drug discovery CRO and Biologics CDMO services<\/a>, we can suggest the best approach to produce a therapeutic antibody,\u201d says Dr. Min. In setting the standard for drug\ndiscovery service delivery, ProBio has worked alongside many pharmaceuticals to provide an end-to-end approach with zero hindrance in drug discovery and production. \u201cOur\ncapability to rapidly develop multi transmembrane targets that are complex and sophisticated for biologics product development with a success rate of above eighty-five percent allows us to continue innovating to serve our clients with even more efficiency,\u201d concludes Dr. Min.<\/p>\n For detailed interview content, please click the link <\/a><\/p>\n Pharma Tech Outlook is a print and digital magazine with over 130,000 qualified subscribers across the APAC, providing a curated platform for technologists and business insiders from the pharmaceutical industry to explore the latest technology trends and understand how their peers leverage new technology.<\/p>"}]}About ProBio Inc<\/h2>\n
ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific<\/h1>\n
\n<\/div>\n\n<\/div>\n\n<\/div>\nAbout Pharma Tech Outlook<\/h2>\n